Decentralized Clinical Trials SIG

Decentralized Clinical Trials (DCT) and hybrid trials are becoming more of a norm given the impact of the COVID-19 pandemic. By creating more patient-centered clinical trials, a decentralized approach can enhance pharma research by attracting a more diverse patient population and eliminating existing barriers to participating in research studies, including COVID-related limitations. Telehealth and remote patient monitoring (RPM) will play an important role in advancing decentralized technology-driven trials. To address this important opportunity to enable equal access to clinical trials by leveraging telehealth and virtual care technologies, the ATA has convened a member special interest group (SIG).